Show simple item record

dc.contributor.authorKwon, M.
dc.contributor.authorKim, S. T.
dc.contributor.authorHong, J. Y.
dc.contributor.authorKim, G.
dc.contributor.authorSmith, S.
dc.contributor.authorMortimer, P. G.
dc.contributor.authorLoembE, B.
dc.contributor.authorDean, Emma J
dc.contributor.authorKang, W. K.
dc.contributor.authorLee, J.
dc.date.accessioned2022-11-30T10:21:25Z
dc.date.available2022-11-30T10:21:25Z
dc.date.issued2022en
dc.identifier.citationKwon M, Kim ST, Hong JY, Kim G, Smith S, Mortimer PG, et al. Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680301211.en
dc.identifier.doi10.1200/JCO.2022.40.16_suppl.4045en
dc.identifier.urihttp://hdl.handle.net/10541/625801
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1200/JCO.2022.40.16_suppl.4045en
dc.titlePhase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric canceren
dc.typeMeetings and Proceedingsen
dc.contributor.departmentDepartment of Hematology-Oncology, Ajou University, Suwon, South Koreaen
dc.identifier.journalJournal of Clinical Oncologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record